Coronary Microvascular Dysfunction in Patients With Heart Failure: Characterization of Patterns in HFrEF Versus HFpEF

Pasquale Paolisso1,2, Emanuele Gallinoro1,3, Marta Belmonte1,2

  • 1Cardiovascular Center Aalst, OLV Hospital, Belgium (P.P., E.G., M.B., D.T.B., K.B., C.D.C., M.S., A.L., G.E., D.F., A.M., L.D., M.P., B.D.B., J.B., M.V.).

Circulation. Heart Failure
|December 18, 2023
PubMed

Insights

Coronary microvascular dysfunction (CMD) impacts heart failure (HF) progression. Invasive assessment revealed distinct CMD patterns in HF with preserved ejection fraction and HF with reduced ejection fraction (HFrEF), predicting reverse remodeling in HFrEF.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Heart Failure Pathophysiology

Background:

  • Coronary microvascular dysfunction (CMD) is a key factor in heart failure (HF) development and worsening.
  • CMD affects HF regardless of ejection fraction or obstructive coronary artery disease.
  • Invasive assessment of CMD offers valuable insights into HF phenotyping and patient prognosis.

Purpose of the Study:

  • To invasively assess coronary flow, microvascular resistance, myocardial perfusion, and reserves in HF patients.
  • To differentiate CMD patterns in HF with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF).

Main Methods:

  • A prospective study of 56 HF patients (21 HFpEF, 35 HFrEF) with nonobstructive coronary artery disease.
  • Invasive assessment of CMD using continuous intracoronary thermodilution, defining CMD as coronary flow reserve <2.5.
  • Quantification of myocardial mass and calculation of myocardial perfusion via echocardiography, CT angiography, and coronary flow measurements.

Main Results:

  • HFrEF patients had significantly higher myocardial mass compared to HFpEF patients.
  • Overall, 52% of patients exhibited CMD, with similar prevalence across HF phenotypes.
  • In HFrEF, CMD presented as functional (low resistance, high flow at rest); in HFpEF, it was structural (high resistance, low flow during hyperemia).
  • CMD independently predicted reduced left ventricular reverse remodeling in HFrEF.

Conclusions:

  • Continuous intracoronary thermodilution effectively defines and characterizes distinct CMD patterns in HF.
  • This method can identify HFrEF patients at higher risk for impaired left ventricular reverse remodeling.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436